Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: September 1, 2026
Principal Office: New York, NY
Event: Regulation FD Disclosure regarding the results of a Method Comparison Study for the Company's Intelligent Fingerprinting Drug Screening System to detect the opiate codeine.
Key Financial Metrics
This filing is a current report regarding a specific operational event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing discloses the issuance of a press release (Exhibit 99.1) announcing the results of a Method Comparison Study. No financial material changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company announced results for its Intelligent Fingerprinting Drug Screening System specifically regarding the detection of codeine.
Legal Disclaimer: The information contained in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless specifically identified.
Risks/Contingencies: No specific risks or contingencies are detailed in the text of this 8-K beyond the standard regulatory disclaimers.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific data and conclusions of the codeine detection study.
- Verify the clinical or regulatory significance of the "Method Comparison Study" results for the Intelligent Fingerprinting Drug Screening System.
- Confirm if these results impact the Company's product roadmap or regulatory approval status.
- Check subsequent filings for any financial impact resulting from this operational update.